Lipotec, S.A.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Peptides useful in the treatment and care of the skin and mucous membranes and their use in cosmetic or pharmaceutical compositions (US 9,067,967) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Jan 14, 2027The maintenance fee for Cosmetic or dermopharmaceutical composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles (US 9,079,048) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for PGC-1α-modulating peptides (US 9,266,921) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors (US 9,315,564) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions (US 9,333,152) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE45,610 | Synthetic peptides reducing or removing bags formed under the lower eye contour and their use in cosmetic or dermopharmaceutical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US RE46,228 | Pigmentation-regulating compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,710,010 | Peptides useful in the treatment and/or care of skin, mucous membranes, scalp and/or hair and their use in cosmetic or pharmaceutical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,079,048 | Cosmetic or dermopharmaceutical composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles In force · From the USPTO record | In force | From the USPTO record | |
| US 8,710,011 | Cosmetic or pharmaceutical peptides containing uncoded amino acids and their use in the treatment and/or care of the skin, mucous membranes, or scalp In force · From the USPTO record | In force | From the USPTO record | |
| US 9,393,186 | Synthetic peptides useful in the treatment of the skin and use thereof in cosmetic or dermopharmaceutical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 8,946,166 | Peptide-based compounds and compositions which inhibit muscle contraction In force · High confidence | In force | High confidence | |
| US 10,758,490 | Nanocapsules containing microemulsions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,067,967 | Peptides useful in the treatment and care of the skin and mucous membranes and their use in cosmetic or pharmaceutical compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,266,921 | PGC-1α-modulating peptides In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 16: 3 patents in force now held by others · 3 lapsed for an unpaid fee · 11 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 no status recorded